Metabolism of paclitaxel in mice
- 1 March 2003
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 14 (3) , 203-209
- https://doi.org/10.1097/00001813-200303000-00003
Abstract
Previous mass balance studies in humans and mice have shown that the fecal and urinary recovery of paclitaxel and known metabolites (3' -hydroxypaclitaxel, 6alpha-hydroxypaclitaxel and 3',6alpha-dihydroxypaclitaxel) was not complete. Obviously this discrepancy is caused by the existence of other yet unknown metabolites. Mdr1a/1b(-/-) mice excrete very low quantities of unchanged paclitaxel. We have therefore used these mice receiving i.v. [3H]paclitaxel to further study the metabolic fate of paclitaxel. The major part of the radiolabel, being 70%, was excreted in the feces. A lipophilic sample, containing about 70% of the radioactivity present in the feces sample, was obtained by diethyl ether extraction. The aqueous residue containing about 30% of the radioactivity was further extracted using methanol. The high-performance liquid chromatography (HPLC) chromatograms of the lipophilic and aqueous sample revealed two and five putative new metabolites of paclitaxel, respectively. The HPLC fractions containing substantial amounts of radioactivity were subjected to tandem mass spectrometry. Two novel monohydroxylated paclitaxel structures were identified, which are probably 2m-hydroxypaclitaxel and 19-hydroxypaclitaxel, structures previously identified in rats. Including these metabolites, about 60% of the mass balance of paclitaxel could be quantified.Keywords
This publication has 10 references indexed in Scilit:
- Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administrationAnti-Cancer Drugs, 2000
- Human liver microsomal metabolism of paclitaxel and drug interactionsEuropean Journal of Drug Metabolism and Pharmacokinetics, 1998
- Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteinsProceedings of the National Academy of Sciences, 1997
- Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human fecesCancer Chemotherapy and Pharmacology, 1995
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differencesCancer Chemotherapy and Pharmacology, 1995
- Taxanes: A New Class of Antitumor AgentsCancer Investigation, 1995
- Paclitaxel metabolites in human plasma and urine: Identification of 6α‐hydroxytaxol, 7‐epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric‐pressure chemical ionization mass spectrometryRapid Communications in Mass Spectrometry, 1995
- Taxol metabolism in rat hepatocytesBiochemical Pharmacology, 1993